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Abstract
Since the introduction of antibiotics into mainstream health care, resistance to these drugs has become a widespread issue
that continues to increase worldwide. Policy decisions to mitigate the development of antimicrobial resistance are hampered
by the current lack of surveillance data on antibiotic product availability and use in low-income countries. This study
collected data on the antibiotics stocked in human (42) and veterinary (21) drug shops in five sub-counties in Luwero district
of Uganda. Focus group discussions with drug shop vendors were also employed to explore antibiotic use practices in the
community. Focus group participants reported that farmers used human-intended antibiotics for their livestock, and
community members obtain animal-intended antibiotics for their own personal human use. Specifically, chloramphenicol
products licensed for human use were being administered to Ugandan poultry. Human consumption of chloramphenicol
residues through local animal products represents a serious public health concern. By limiting the health sector scope of
antimicrobial resistance research to either human or animal antibiotic use, results can falsely inform policy and intervention
strategies. Therefore, a One Health approach is required to understand the wider impact of community antibiotic use and
improve overall effectiveness of intervention policy and regulatory action.
Description
Chloramphenicol is a phenicol class antibiotic with a nar-
row margin of safety used in small animal and human
medicine [1]. Human oral bioavailability of crystalline
chloramphenicol and chloramphenicol palmitate is
approximately 80% [2], with rapid absorption and extensive
distribution [3, 4]. Many countries have banned its use in
livestock because human consumption of animal products
containing chloramphenicol residues can cause idiosyn-
cratic aplastic (non-regenerative) anemia [1, 5], which while
uncommon, can be fatal due to its irreversible nature
[1, 4–6]. Moreover, the adverse drug reaction is not dose-
dependent and no safe consumption level has been estab-
lished [4]. Additionally, chloramphenicol is considered to
have potential carcinogenic effects [6]. Given these safety
concerns, chloramphenicol is seldom used in humans and
“reserved for severe, life-threatening infections for which
other antibiotics are not available” [4].
In Uganda, National Clinical Guidelines reserve human
oral chloramphenicol for use in hospitals while ear and
ophthalmic preparations are permitted in primary healthcare
facilities, including level II health centers [7, 8]. Enforcing
antibiotic use (ABU) guidelines is difficult as Uganda’s
formal healthcare sector is supplemented by private drug
shops [9]. Drug shops provide crucial healthcare services in
many low- and middle-income countries (LMICs) where
drug shop vendors (DSVs) act as informal healthcare pro-
viders, advising patients on drug choice and dosing
instructions [9–12]. Community-based drug shops often
provide a more reliable drug stock than higher-level
healthcare facilities, with convenient locations, lower
costs, and short waiting times [11]. Thus, drug shops
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represent an important source of antibiotics for
many communities.
Although regulations prohibit Ugandan drug shops from
selling antibiotics for human use without a prescription [13],
this practice is widespread and seen in other LMICs [9–11,
14–16]. In contrast, veterinary drug shops can legally sell
antibiotics over-the-counter which are used by farmers
without veterinary consultation [17]. There is no formal
chloramphenicol use ban in Ugandan livestock through The
National Drug Policy and Authority Act, Section 64 (NDA,
2016), which regulates and restricts the use of classified
drugs for agricultural purposes. However, the NDA does not
permit veterinary drug shops to sell chloramphenicol for
livestock use (Luwero district veterinary representative,
personal communication). Nevertheless, our study provides
evidence that livestock chloramphenicol use is common in
Uganda and these activities should be investigated further.
A mixed qualitative and quantitative study conducted in
Ugandan human and veterinary drug shops described
human-intended chloramphenicol products being adminis-
tered to livestock. This was discovered during a larger study
investigating antibiotic availability and DSV views
regarding treatment efficacy and antimicrobial resistance
(AMR). All participation was voluntary and followed full
informed consent and assurance of data confidentiality.
Structured questionnaires including a complete antibiotic
inventory were conducted with DSVs in 21 veterinary drug
shops and 42 human drug shops, during May-June 2018.
Three human DSVs declined participation due to concerns
around reporting antibiotic sales. Six focus group discus-
sions (FGDs) were held; two FGDs with veterinary DSVs
and four with human DSVs.
No chloramphenicol was found in the antibiotic inven-
tories of all 21 veterinary drug shops surveyed, indicating
successful enforcement of restricting chloramphenicol sales
through veterinary drug shops. Chloramphenicol formula-
tions (oral, ear, and ophthalmic preparations) were found in
71.4% (30/42) of the human drug shops. While sector-
specific antibiotic inventory lists are critical for under-
standing availability, these should not be considered strictly
independent concerning ABU. It became evident during
FGDs that off-label chloramphenicol use in livestock with
human-licensed formulations was occurring. This was part
of a wider phenomenon we term off-label “crossover-use”,
in which human-intended antibiotic products were pur-
chased from human drug shops for animal use, and simi-
larly, veterinary antibiotic formulations were purchased for
human use. Strikingly, descriptions of off-label crossover-
use were frequently unprompted and depicted in all six
FGDs as a widespread community practice. Use of chlor-
amphenicol from human drug shops in poultry was
described as exceedingly common, where “chloramphenicol
is now know[n] as poultry capsules” (FGD III, Human
DSVs), with commonly reported indications being fever
and cough.
“…they will tell you that antibiotics meant for chicken
don’t work and the human antibiotics tends to work
on chicken more effectively” – FGD I, Human DSVs
Chloramphenicol crossover-use could be partially eco-
nomically driven. Chloramphenicol sold in human drug
shops provides a cheaper alternative to purchasing large
packets of veterinary antibiotic formulations, in addition to
more convenient sizes for small-scale farmers. In our
inventory data, it cost 100 to 200 UGX (0.02 to 0.04 GBP1)
per 250 mg chloramphenicol tablet. Comparatively, veter-
inary antibiotics were sold in 100 g packets and cost
between 10,000 and 30,000 UGX (2.00 to 6.00 GBP),
depending on the drug. If farmers are unaware of adverse
health effects caused by chloramphenicol residue con-
sumption, they may consider human-intended formulations
as a viable and cost-effective alternative.
“One of the challenges is that one I have told you that
veterinary drugs have no small packages and there are
very many small scale farmers… our farmers are not
commercial farmers, they are subsistence small scale
farmers yet we do not have many of the vet drugs in
such small packages.” – FGD II, Veterinary DSVs
Additionally, professional medical advice is not always
accessible in sub-Saharan Africa, including Uganda, where
veterinary services are fragmented [17]. Therefore, farmers
are more likely to seek out alternative medical advice.
Geographical access also represents a potential barrier to
appropriate ABU. In our experience, human drug shops
were much more abundant in rural regions; therefore, more
accessible than their veterinary counterparts.
If chloramphenicol crossover-use is as rampant as FGDs
described, the development of chloramphenicol resistance
in poultry may have occurred. High levels of
chloramphenicol-resistant Escherichia coli isolates were
reported in Ugandan broiler chickens in 2010 (41% in Lira
District, 42% in Kampala) [18]. Moreover, there is potential
for cross-resistance development between chloramphenicol,
florfenicol, linezolid, lefamulin, and tiamulin, important
antibiotics in human and veterinary medicine, due to similar
mechanism of action [19, 20]. However, the relationship
between ABU and cross-resistance through alteration of
similar binding sites is not straightforward [19], and cross-
resistance between these antibiotics is rarely reported [20,
21]. However, florfenicol, linezolid, lefamulin, or tiamulin
were not found in any human or veterinary drug
1 Conversion rate of 1.00UGX= 0.0002 GBP, December 2020
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shop surveyed nor were these reported to be used in live-
stock by DSVs. As chloramphenicol was not sold in any
veterinary drug shops (0/21), but chloramphenicol was
present in 71.4% (30/42) of human drug shops, it is con-
ceivable that this resistance developed in part due to
chloramphenicol crossover-use. Though, it also cannot be
excluded that chloramphenicol or related resistance causing
antibiotics were previously more accessible in veterinary
drug shops. Nonetheless, mounting concern regarding the
global threat of AMR underlines the urgency to reduce
antibiotic misuse wherever possible. As resistance to anti-
biotics of public health importance can develop with con-
tinued chloramphenicol use, this highlights the need for
monitoring and addressing antibiotic crossover-use in ani-
mals, as this is often overlooked.
Furthermore, chloramphenicol residues in animal pro-
ducts represent a danger to the community. Continued
access to chloramphenicol for livestock in areas without
rigorous antibiotic residue monitoring could lead to serious
health challenges beyond AMR. High-levels of antibiotic
residues (sulfamethazine and sulfadiazine) in eggs entering
the food-chain in Uganda were detected [22], and concerns
regarding antibiotic residues were raised in our FGDs.
Veterinary DSVs claimed disregarding antibiotic with-
drawal guidelines was “very common because we don’t
have enforcement and regulatory mechanisms” (FGD II,
Veterinary DSVs). This represents a potential consumer
health risk that demands further investigation and attention
from policymakers.
There is little information on continued chloramphenicol
use in other countries. Only two studies were identified,
both from Nigeria; Adebowale et al. [23], found that 44 of
103 (42.7%) of poultry farmers (layer hens) used chlor-
amphenicol, though the chloramphenicol source was not
stated. Omeiza et al. [24] confirmed that 15 out of 105
(14.5%) poultry farms reported using human-intended
chloramphenicol products. It is clear that while the chlor-
amphenicol ban in livestock is widespread, full adherence
has not necessarily been achieved.
Reported off-label crossover-use highlights the impor-
tance of a One Health approach in AMR research and
policy. If ABU research is limited to one sector or species,
the full spectrum of community ABU would not be
described. Likewise, if policy formulation, regulation, and
enforcement aimed to address antibiotic misuse have a
single sector focus, this could limit effectiveness.
Our findings suggest a lack of knowledge transfer
regarding the potential adverse health effects of chlor-
amphenicol residues to consumers and poor implementation
of regulatory policy within and across sectors. It is
unknown whether the rationale behind the sales ban was
directly communicated to relevant stakeholders when initi-
ated. Though from its continued widespread use, it appears
this was not the case. Without fully informing the ultimate
end users about the reason behind policy changes, bans may
be ineffective.
These findings raise several policy considerations;
including the need to communicate the rationale behind
public health policy to end-users, concerns regarding food
safety risks of chloramphenicol residues, and the impor-
tance of One Health approaches in research, and policy.
These findings should be a call to action to alert farmers of
the dangers of using chloramphenicol in livestock and an
educational campaign should be initiated to communicate
this urgent public health risk. DSVs have an important
role in educating their customers to promote responsible
ABU. As 50.0% and 23.8% of the human and veterinary
DSVs, respectively, reported participating in continuing
education workshops or courses, this represents an
opportunity for discussing crossover-use. Furthermore,
enforcement of the chloramphenicol ban should be
extended to human drug shops to halt the continued use of
chloramphenicol in livestock supported by awareness
campaigns for the potential public health risks to enhance
compliance. Safer treatment alternatives exist in the
human health sector both within and external to the phe-
nicol class of antibiotics [1, 3]. The need for improvement
in education and enforcement was acknowledged by the
DSVs.
“… I think it would be our role as both human and
veterinary system to guide our clients before we sell
the drugs to them, more so the human drugs would
only be sold on prescription only but this open system
of ours is the one causing problems where people
come in as they wish, buy drugs and take.” – FGD II,
Veterinary DSVs
Clearly, ABU is not limited to the intended species or
sector, which poses a challenge for enforcement. Addi-
tionally, while chloramphenicol sales are banned specifi-
cally in veterinary drug shops, and along with all antibiotics
in human drug shops, unrestricted chloramphenicol avail-
ability represents a gap in enforcement. Increasing knowl-
edge regarding crossover-use implications may in part
mitigate the issue; however, some enforcement will likely
be required. Therefore, to be successful, enforcement
capacity must be increased, both in regard to antibiotic sales
and compliance to antibiotic withdrawal periods in
livestock.
It is clear that the described findings represent a gap
between policy intention and effective outcome, where a
One Health approach is required. While inappropriate ABU
contributes to AMR, without immediate action, this finding
could lead to the continuation of additional adverse health
consequences arising from antibiotic misuse.
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